The stock market's strength is mainly due to mega-cap tech companies and AI leaders, which hide underlying weaknesses in the real economy caused by rising interest rates and supply-driven inflation. Smaller and mid-sized companies are facing significant challenges from tariffs, higher fuel costs, and increased financing expenses, which reduce their investment incentives. Transportation and industrial stocks have notably underperformed, indicating market caution despite the S&P 500 reaching new highs. The author remains optimistic about cyclical and real-economy stocks, viewing current difficulties as buying opportunities if geopolitical tensions, particularly related to Iran, ease.
The near-record stock market and its biggest risks are shown in Pluang's Industrials sector data for September 23, 2026. Of 92 priced Industrials stocks, 29 rose and 56 fell, indicating more declines than gains. Notable movers include Allegion PLC at USD 151.73 with a 1-day change of -1.44%, Ryanair Holdings plc at USD 55.18 with a 100% sell order activity, and Vertiv Holdings Co at USD 250.52 with a 54% buy order activity, as of 18:12 WIB.
RBC Capital assigned Fastly a "Sector Perform" rating, signaling a neutral investment outlook. Fastly aims to grow its revenue to $1.1-$1.3 billion by 2029, driven by steady operational improvements and a $22 billion market opportunity. The company i...
Cracker Barrel Old Country Store reported quarterly earnings of $0.99 per share, far exceeding analyst expectations of $0.17. The company also posted revenue of $849.34 million, beating estimates of $844.99 million, driven by strong sales growth. Thi...
AutoZone reported mixed Q4 results with sales up 5.6% to $6.6 billion, missing expectations, but earnings per share rose 15.1% to $56.05, surpassing forecasts. Despite the sales shortfall, the stock rose 6% as the profit beat boosted investor confide...
General Mills reported fiscal Q1 earnings with an EPS of $0.75, beating analyst expectations of $0.72, and revenue of $4.39 billion, surpassing the $4.35 billion estimate. The strong revenue was driven by increased demand for pantry staples and break...
Amgen's stock price target was raised to $410 following positive results from its experimental drug dazodalibep in a late-stage trial for Sjögren's disease. The drug showed significant improvement in patients' symptoms, with effects seen as early as ...
